SecBot SecBot
8-K ·Filed Jun 4, 2026

SRPT

Sarepta Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed5mo ago SEC0001193125-26-257501
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine annual meeting filing with no material financial data or guidance. The equity plan approvals are standard governance, monitor for future 10-Q filings to track actual share issuance under the new plans. No immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$15.75
T+0 close · Jun 4, 2026 · via day close
Latest settled
+33.30%
T+60 · $21.00
Vs SPY
+29.30%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 5 $15.75entry
  2. T+1 · 5mo ago −1.27%α −1.50% · $15.55
  3. T+5 · 5mo ago −2.79%α −3.36% · $15.31
  4. T+20 · 4mo ago +21.78%α +19.92% · $19.18
  5. T+60 · 3mo ago +33.30%α +29.30% · $21.00

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sarepta Therapeutics held its 2026 annual meeting on June 4, 2026. Stockholders approved the new 2026 Equity Incentive Plan (authorizing up to 6,286,841 shares for issuance) and the 2026 Employee Stock Purchase Plan (1,500,000 shares), replacing prior plans. All director nominees were elected, and KPMG was ratified as auditor. This is a routine governance filing with no material financial impact.

Key Facts

  • Stockholders approved the 2026 Equity Incentive Plan, authorizing up to 6,286,841 shares of common stock for issuance under awards.
  • Stockholders approved the 2026 Employee Stock Purchase Plan, authorizing up to 1,500,000 shares of common stock for purchase by employees.
  • All five director nominees were elected: Douglas S. Ingram, Hans Wigzell, Kathryn J. Boor, Michael Chambers, and Deirdre Connelly.
  • Advisory vote on named executive officer compensation for 2025 was approved (45,185,398 For, 22,373,065 Against).
  • KPMG LLP was ratified as independent registered public accounting firm for fiscal year ending December 31, 2026 (79,907,368 For, 2,110,136 Against).
  • Record date for the meeting was April 8, 2026, with 105,571,146 shares outstanding; 77.97% quorum achieved.

Financial Impact

No financial figures reported. The equity plan authorizes up to 6,286,841 shares (approximately 6.0% of outstanding shares) for future equity compensation, and the ESPP authorizes up to 1,500,000 shares (approximately 1.4% of outstanding) for employee stock purchases at a 15% discount.

dilutionshare count

Risk Factors

  • Potential dilution from future equity awards under the 2026 Plan (up to ~6% of outstanding shares).
  • Advisory say-on-pay vote showed 33% opposition (22.4M against), indicating some shareholder dissatisfaction with executive compensation.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
39% bullish (33 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-257501
Document: d88936dex102.htm0001193125-26-257501
Document: d88936d8k.htm0001193125-26-257501
Document: 0001193125-26-257501-index-headers.html0001193125-26-257501
Document: 0001193125-26-257501-index.html0001193125-26-257501
Document: 0001193125-26-257501.txt0001193125-26-257501

US Market Status

Market Closed · Opens Wed (9h 53m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 4, 2026